Expression of TweakR in Breast Cancer and Preclinical Activity of Enavatuzumab, a Humanized Anti-TweakR MAb

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2012 Oct 18

PMID 23073510

Citations 22

Authors

Debra T Chao

Mian Su

Sonia Tanlimco

Mien Sho

Donghee Choi

Mel Fox

Shiming Ye

Eric D Hsi

Lisa Durkin

Johnny Yin

Yongke Zhang

Han Kim

Gary C Starling

Patricia A Culp

Affiliations

Soon will be listed here.

Abstract

Background: The receptor for the cytokine TWEAK (TweakR) is a cell surface member of the tumor necrosis factor receptor superfamily with diverse biological roles. TNFRSF family members are appealing therapeutic targets in oncology due to their aberrant expression and function in tumor cells. The goal of the current study was to examine the potential of TweakR as a therapeutic target in breast cancer.

Methods: Expression of TweakR in primary breast cancer tissues and metastases was characterized using immunohistochemistry. To determine the functional relevance of TweakR, breast cancer cell lines were treated in vitro and in vivo with enavatuzumab, a humanized mAb against TweakR.

Results: Overexpression of TweakR was observed in infiltrating tumors compared to normal adjacent breast tissues, and strong staining of TweakR was observed in all subtypes of invasive ductal breast cancer. In addition, a positive correlation of TweakR and HER2 expression and co-localization were observed, irrespective of ER status. TweakR expression was also observed in bone metastasis samples from primary breast cancer but rarely in benign tumors. Enavatuzumab inhibited the in vitro growth of TweakR-expressing breast cancer cell lines, and this activity was augmented by cross-linking the mAb. In addition, enavatuzumab significantly inhibited the in vivo growth of multiple breast cancer xenograft models including a model of metastasis.

Conclusions: TweakR is highly expressed in all subtypes of invasive ductal breast cancer, and enavatuzumab administration exhibited a dose-dependent inhibition of primary tumor growth and lung metastasis and enhanced the antitumor activity of several chemotherapy agents currently used to treat breast cancer. These data provide the rationale to evaluate enavatuzumab as a potential therapy for the treatment of breast cancer.

Citing Articles

Mechanisms and pharmacotherapy of cancer cachexia-associated anorexia.

Sato R, da Fonseca G, das Neves W, von Haehling S Pharmacol Res Perspect. 2025; 13(1):e70031.

PMID: 39776294 PMC: 11707257. DOI: 10.1002/prp2.70031.

TWEAK/Fn14 signalling driven super-enhancer reprogramming promotes pro-metastatic metabolic rewiring in triple-negative breast cancer.

Sim N, Carter J, Deka K, Tan B, Sim Y, Tan S Nat Commun. 2024; 15(1):5638.

PMID: 38965263 PMC: 11224303. DOI: 10.1038/s41467-024-50071-z.

Targeting fibroblast growth factor (FGF)-inducible 14 (Fn14) for tumor therapy.

Zaitseva O, Hoffmann A, Otto C, Wajant H Front Pharmacol. 2022; 13:935086.

PMID: 36339601 PMC: 9634131. DOI: 10.3389/fphar.2022.935086.

Antibody-drug conjugates harboring a kinesin spindle protein inhibitor with immunostimulatory properties.

Sommer A, Berndt S, Lerchen H, Forveille S, Sauvat A, Mumberg D Oncoimmunology. 2022; 11(1):2037216.

PMID: 35154909 PMC: 8837233. DOI: 10.1080/2162402X.2022.2037216.

Recombinant SLAMblind Measles Virus Is a Promising Candidate for Nectin-4-Positive Triple Negative Breast Cancer Therapy.

Fujiyuki T, Amagai Y, Shoji K, Kuraishi T, Sugai A, Awano M Mol Ther Oncolytics. 2020; 19:127-135.

PMID: 33145396 PMC: 7585052. DOI: 10.1016/j.omto.2020.09.007.

References

Tran N, McDonough W, Donohue P, Winkles J, Berens T, Ross K . The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol. 2003; 162(4):1313-21. PMC: 1851233. DOI: 10.1016/S0002-9440(10)63927-2. View

Hurvitz S . Evolving options for the treatment of metastatic breast cancer: progression-free survival as an endpoint. Cancer Treat Rev. 2011; 37(7):495-504. PMC: 3821870. DOI: 10.1016/j.ctrv.2011.01.002. View

Weng W, Levy R . Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol. 2003; 21(21):3940-7. DOI: 10.1200/JCO.2003.05.013. View

Cleator S, Heller W, Coombes R . Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007; 8(3):235-44. DOI: 10.1016/S1470-2045(07)70074-8. View

Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P . Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002; 99(3):754-8. DOI: 10.1182/blood.v99.3.754. View

Winkles J . The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov. 2008; 7(5):411-25. PMC: 3018765. DOI: 10.1038/nrd2488. View

Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G . Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res. 2007; 67(24):11991-9. DOI: 10.1158/0008-5472.CAN-07-2068. View

Feng S, Guo Y, Factor V, Thorgeirsson S, BELL D, Testa J . The Fn14 immediate-early response gene is induced during liver regeneration and highly expressed in both human and murine hepatocellular carcinomas. Am J Pathol. 2000; 156(4):1253-61. PMC: 1876890. DOI: 10.1016/S0002-9440(10)64996-6. View

Neve R, Chin K, Fridlyand J, Yeh J, Baehner F, Fevr T . A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006; 10(6):515-27. PMC: 2730521. DOI: 10.1016/j.ccr.2006.10.008. View

10.

Wilson N, Yang B, Yang A, Loeser S, Marsters S, Lawrence D . An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells. Cancer Cell. 2011; 19(1):101-13. DOI: 10.1016/j.ccr.2010.11.012. View

11.

de Haij S, Jansen J, Boross P, Beurskens F, Bakema J, Bos D . In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling. Cancer Res. 2010; 70(8):3209-17. DOI: 10.1158/0008-5472.CAN-09-4109. View

12.

Schneider P, Schwenzer R, Haas E, Muhlenbeck F, Schubert G, Scheurich P . TWEAK can induce cell death via endogenous TNF and TNF receptor 1. Eur J Immunol. 1999; 29(6):1785-92. DOI: 10.1002/(SICI)1521-4141(199906)29:06<1785::AID-IMMU1785>3.0.CO;2-U. View

13.

Motoki K, Mori E, Matsumoto A, Thomas M, Tomura T, Humphreys R . Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin Cancer Res. 2005; 11(8):3126-35. DOI: 10.1158/1078-0432.CCR-04-1867. View

14.

Nakayama M, Ishidoh K, Kayagaki N, Kojima Y, Yamaguchi N, Nakano H . Multiple pathways of TWEAK-induced cell death. J Immunol. 2002; 168(2):734-43. DOI: 10.4049/jimmunol.168.2.734. View

15.

Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K . Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol. 2002; 170(1):341-8. DOI: 10.4049/jimmunol.170.1.341. View

16.

Chacon M, Richart C, Gomez J, Megia A, Vilarrasa N, Fernandez-Real J . Expression of TWEAK and its receptor Fn14 in human subcutaneous adipose tissue. Relationship with other inflammatory cytokines in obesity. Cytokine. 2006; 33(3):129-37. DOI: 10.1016/j.cyto.2005.12.005. View

17.

Jakubowski A, Ambrose C, Parr M, Lincecum J, Wang M, Zheng T . TWEAK induces liver progenitor cell proliferation. J Clin Invest. 2005; 115(9):2330-40. PMC: 1187931. DOI: 10.1172/JCI23486. View

18.

Campbell S, Michaelson J, Burkly L, Putterman C . The role of TWEAK/Fn14 in the pathogenesis of inflammation and systemic autoimmunity. Front Biosci. 2004; 9:2273-84. DOI: 10.2741/1395. View

19.

Hurvitz S, Finn R . What's positive about 'triple-negative' breast cancer?. Future Oncol. 2009; 5(7):1015-25. DOI: 10.2217/fon.09.68. View

20.

Drobyski W, Gottlieb M, Carrigan D, Ostberg L, Grebenau M, Schran H . Phase I study of safety and pharmacokinetics of a human anticytomegalovirus monoclonal antibody in allogeneic bone marrow transplant recipients. Transplantation. 1991; 51(6):1190-6. DOI: 10.1097/00007890-199106000-00009. View